BioNano Genomics Inc vs FMC Corp — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.20M), while FMC Corp trades at $10.79 (market cap $1.34B). The key difference: FMC Corp is far larger — about 101.5× BioNano Genomics Inc's market cap, and FMC Corp pays a 2.99% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | FMC | |
|---|---|---|
Market Cap | $13.20M | $1.34B |
Sector | Health | Basic Materials |
52-Week High | $4.92 | $43.90 |
52-Week Low | $1.09 | $10.72 |
Enterprise Value | $15.81M | $5.49B |
Dividend Yield | — | 2.99% |
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
FMC Corporation (FMC) trades at $10.91 with no change in the latest session. The agricultural sciences company shows mixed signals with a bearish technical outlook but positive analyst sentiment (47.6% buy ratings). Recent developments include a $400 million minority investment from Tessenderlo Group and regulatory submissions for new herbicide technology. However, fundamental challenges persist with negative net income margin of -72.93% and declining revenue from $5.8B in 2022 to $3.47B in 2025.
The stock presents a turnaround opportunity with attractive valuation metrics (P/S 0.4x, P/B 0.75x) and significant upside to the $16 consensus price target. Key risks include continued revenue declines, negative cash flow from operations, and high debt levels. The company's strategic moves to reduce debt and advance new products could drive recovery if execution improves.
Trailing returns across standard periods
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →